An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

Clinical Trial ID: NCT03964168

Patient interviews to evaluate the reason patients discontinue biologic therapy and/or fail to follow up with provider.

Retrospective chart review and patient interviews to evaluate the reason patients discontinue biologic therapy and/or fail to follow up with provider. This research intends to improve the continuity of care by determining why patients stop therapy and what can be done to improve their experience with the provider, pharmaceutical companies and specialty pharmacies.

Inclusion Criteria: - Male or female adults ≥ 18 years of age. - Was receiving first or second biologic therapy - Has not had a follow up with treating physician in ≥ 9 months Exclusion Criteria: - Actively receiving biologic therapy - Was not receiving first or second biologic therapy

Start Date
2019-05-14
Last Updated
2019-05-24
Sponsor
Janssen Scientific Affairs, LLC
Condition Name
Psoriasis

Learn about this trial.

Check the eligibility requirements, study details, and more.

Visit clinicaltrials.gov

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.

Clinicaltrials.gov

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Trial Type

Interventional

Trial Phase

Phase 4

Sponsorship

LEO Pharma

Clinicaltrials.gov

Immunogenetic Profiling of Goeckerman Therapy in the Treatment of...

This study examines the effect of Goeckerman therapy (a combination of phototherapy and topical crude coal tar), crude coal tar alone, and phototherapy alone on the immunologic and genetic environment within...

Trial Type

Interventional

Trial Phase

Phase 4

Sponsorship

National Psoriasis Foundation

Clinicaltrials.gov

Linking Epidermal Barrier Function With Anti-Oxidant Defense...

Investigators will sample the skin and blood of patients with chronic skin conditions (including but not limited to atopic dermatitis (AD), contact dermatitis, hidradenitis suppurativa (HS), and psoriasis) to...

Trial Type

Observational

Sponsorship

University of Arizona

Clinicaltrials.gov

Apremilast Pregnancy Exposure Registry

The purpose of the Apremilast Pregnancy Exposure Registry is to monitor planned and unplanned pregnancies exposed to apremilast and to evaluate the safety of this medication relative to specified pregnancy...

Trial Type

Observational [Patient Registry]

Sponsorship

The Organization of Teratology Information Specialists

Clinicaltrials.gov

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric...

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis. At least...

Trial Type

Interventional

Trial Phase

Phase 3

Sponsorship

Celgene

Clinicaltrials.gov

The Psoriasis, Atherosclerosis, and Cardiometabolic Disease...

Background: - Cardiometabolic diseases are medical disorders that can occur together and affect the heart. They increase the risk of developing heart disease and diabetes. One disorder, psoriasis, is an...

Trial Type

Observational

Sponsorship

National Heart, Lung, and Blood Institute (NHLBI)

Clinicaltrials.gov

Apremilast as a Direct Treatment for Mild-to-moderate Plaque...

This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis....

Trial Type

Interventional

Trial Phase

Phase 3

Sponsorship

Celgene

Clinicaltrials.gov

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque...

This is a phase IV, single-center, open label, single arm study in which a group of 30 subjects with moderate to severe plaque psoriasis will receive secukinumab therapy. Non-invasive imaging with optical...

Trial Type

Interventional

Trial Phase

Phase 4

Sponsorship

Novartis

Clinicaltrials.gov

Assess the Potential for Adrenal Suppression and Systemic Drug...

The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

Encore Dermatology, Inc.

Clinicaltrials.gov

Asthma and Atopic Dermatitis Validation of PROMIS Pediatric...

This is designated to validate patient-reported outcomes (PRO) measures in itch-specific pediatric skin conditions, such as atopic dermatitis, and examine the ability of a modified stigma instrument to assess...

Trial Type

Interventional

Trial Phase

N/A

Sponsorship

Regeneron Pharmaceuticals

Clinicaltrials.gov

Videocapillaroscopy Assessment During Systemic Agent Therapy in...

The aim of this study is to determine if videocapillaroscopy could be used as an objective and reliable method to assess psoriasis severity and to document improvement during treatment by measuring changes in...

Trial Type

Observational

Sponsorship

AbbVie

Clinicaltrials.gov

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects...

This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with moderate to severe genital psoriasis (modified sPGA-G...

Trial Type

Interventional

Trial Phase

Phase 3

Sponsorship

Celgene

Clinicaltrials.gov

Psoriatic Arthritis and Psoriasis Treatment Decision Aid

The purpose of this study is to create and test a patient decision aid that facilitates the shared decision-making process when patients with psoriasis and/or psoriatic arthritis are starting or switching to a...

Trial Type

Interventional

Trial Phase

N/A

Sponsorship

Pfizer

Clinicaltrials.gov

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75...

Trial Type

Interventional

Trial Phase

Phase 4

Sponsorship

Celgene Corporation

Clinicaltrials.gov

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in...

This will be a single-center, randomized, double-blinded, vehicle-controlled clinical study to determine the efficacy of Enstilar® foam, a combination of calcipotriene and betamethasone dipropionate...

Trial Type

Interventional

Trial Phase

Phase 4

Sponsorship

Icahn School of Medicine at Mount Sinai

Clinicaltrials.gov

Safety and Efficacy of Secukinumab in Mild Psoriasis

Mild psoriasis not only progresses to moderate-to-severe psoriasis but also precedes systemic inflammation that leads to psoriatic arthritis and cardiovascular comorbidities. By curing mild psoriasis with a...

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

Novartis

Clinicaltrials.gov

The Role of Food Sensitivity in Psoriasis

Psoriasis is a common chronic skin disorder that affects over 4 million people. There is no cure for psoriasis and treatment is directed at controlling patients' symptoms. The purpose of this study is to...

Trial Type

Interventional

Trial Phase

N/A

Sponsorship

University of Michigan

Clinicaltrials.gov

Apremilast in Combination With Clobetasol Spray for the Treatment of...

Researchers want to find out if giving the drug Apremilast in combination with Clobetasol spray can help people clear their moderate to severe plaque psoriasis quicker than if Apremilast is used by itself.

Trial Type

Interventional

Trial Phase

Phase 4

Sponsorship

Washington Dermatology Center

Clinicaltrials.gov

Once-Weekly Oral Aminopterin for the Treatment of Subjects With...

This study evaluates the treatment of psoriasis with aminopterin. Participants will be treated for 14 weeks with either aminopterin or placebo followed. The participants will not know if they are being treated...

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

National Institute of Allergy and Infectious Diseases (NIAID)

Clinicaltrials.gov

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband...

A single center study of 30 patient receiving Narrowband UVB phototherapy three times weekly for 12 weeks. Patients will be evaluated through week 36 to evaluate maintenance of response.

Trial Type

Interventional

Trial Phase

N/A

Sponsorship

Psoriasis Treatment Center of Central New Jersey

Clinicaltrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics,...

This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and immunogenicity of CC-90006 following...

Trial Type

Interventional

Trial Phase

Phase 1

Sponsorship

Celgene

Clinicaltrials.gov

The Role of Bacterial Toxins in Human Skin Disease

Atopic dermatitis and psoriasis are two skin diseases often associated with bacterial infections and inflammation. Studies indicate that skin cells from these patients may have some changes that make these...

Trial Type

Observational

Sponsorship

National Jewish Health

Clinicaltrials.gov

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis

The purpose of this study is to determine the anti-inflammatory effect of high-dose riboflavin supplementation on chronic plaque psoriasis. Psoriasis is a common chronic skin disorder that affects over 4...

Trial Type

Interventional

Trial Phase

Phase 2

Sponsorship

University of Michigan

An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers

Description

Criteria

Start Date

Last Updated

Sponsor

Condition Name

Learn about this trial.

Related Trials

Clinicaltrials.gov

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

Clinicaltrials.gov

Immunogenetic Profiling of Goeckerman Therapy in the Treatment of...

Clinicaltrials.gov

Linking Epidermal Barrier Function With Anti-Oxidant Defense...

Clinicaltrials.gov

Apremilast Pregnancy Exposure Registry

Clinicaltrials.gov

Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric...

Clinicaltrials.gov

The Psoriasis, Atherosclerosis, and Cardiometabolic Disease...

Clinicaltrials.gov

Apremilast as a Direct Treatment for Mild-to-moderate Plaque...

Clinicaltrials.gov

Secukinumab Therapy for the Treatment of Moderate to Severe Plaque...

Clinicaltrials.gov

Assess the Potential for Adrenal Suppression and Systemic Drug...

Clinicaltrials.gov

Asthma and Atopic Dermatitis Validation of PROMIS Pediatric...

Clinicaltrials.gov

Videocapillaroscopy Assessment During Systemic Agent Therapy in...

Clinicaltrials.gov

An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects...

Clinicaltrials.gov

Psoriatic Arthritis and Psoriasis Treatment Decision Aid

Clinicaltrials.gov

Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis

Clinicaltrials.gov

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in...

Clinicaltrials.gov

Safety and Efficacy of Secukinumab in Mild Psoriasis

Clinicaltrials.gov

The Role of Food Sensitivity in Psoriasis

Clinicaltrials.gov

Apremilast in Combination With Clobetasol Spray for the Treatment of...

Clinicaltrials.gov

Once-Weekly Oral Aminopterin for the Treatment of Subjects With...

Clinicaltrials.gov

An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband...

Clinicaltrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics,...

Clinicaltrials.gov

The Role of Bacterial Toxins in Human Skin Disease

Clinicaltrials.gov

The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis